ANTIBIOTIC DOXYCYCLINE

Chemical Market Reporter, April, 1998

ANTIBIOTIC DOXYCYCLINE- Food and Drug Administration has sent Atrix Laboratories Inc. a letter of approval for using its Atridox drug to treat periodontal disease. The letter states that Atridox has met the necessary requirements for final approval. The product combines the antibiotic doxycycline with Atrix's proprietary drug delivery system.

Pending final FDA approval, Block Drug Corporation will market Atridox in the US, according to its North American marketing agreement with Atrix. In return, Block will give Atrix a $7 million milestone payment as well as manufacturing margins and sales royalties. Atrix is also developing a strategic distribution channel for ir marketing its dental products outside of Block's licensed territories.